Novel Antidepressant Drugs, Arterial Hypertension and Cardiovascular Disease
Vasiliki K. Katsi, Maria Marketou, Georgia Vamvakou, Thomas Makris, Dimitris Tousoulis, Christodoulos I. Stefanadis, Panos Vardas and Ioannis E. KallikazarosAffiliation:
Cardiology Department, Hippokration Hospital, Greece, Vas. Sofias Avenue 114, Post code: 11527, Athens, Greece.
AbstractDepression is a common mental health issue worldwide leading to disability, functional decline and increased mortality. Novel antidepressants have been developed during the last decades in order to treat depression syndromes. Some evidence suggests that major depression has been associated with the development of congestive heart failure and with adverse outcomes in patients with coronary heart disease. The purpose of the present article is to review the impact of novel antidepressant patent drugs on cardiovascular disease and arterial hypertension.
Arterial hypertension, bupropion, cardiovascular disease, depression, fluoxetine, norepinephrine reuptake inhibitors, serotonin reuptake inhibitors.
Purchase Online Order Reprints Order Eprints Rights and Permissions